Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Jul 2011

Bonardi Renato, Tabone Marco, Manca Aldo, Pellicano Rinaldo, Ciancio Alessia, Rizzetto Mario

Abstract excerpt

BACKGROUND: In patients with chronic hepatitis C, rapid HCV-RNA clearance under treatment might allow shorter treatment duration without modifying the sustained virological response (SVR) rate. This study evaluated the impact of rapid virological response (RVR) in HCV genotype 1b infection management. METHODS: In an open-label trial, 180 patients received standard doses of peginterferon alfa-2a plus ribavirin....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C Antibodies

Share to Interferon-alpha

Share to Liver Function Tests

Share to Polyethylene Glycols

Share to Recurrence

Share to Ribavirin

Source

Identifiers

PMID: 21723079
DOI: 10.1016/j.biopha.2011.03.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.PMID 21723079Read ↗

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.Semantic proximity Read ↗

Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.Semantic proximity Read ↗

Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.Semantic proximity Read ↗

Reducing treatment duration in patients infected with hepatitis C genotype 1: any need for further studies?Semantic proximity Read ↗

Tailoring treatment duration to 12 to 16 weeks in hepatitis C genotype 2 or 3 with rapid virologic response: systematic review and meta-analysis of randomized controlled trials.Semantic proximity Read ↗

Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection.Semantic proximity Read ↗

Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.Semantic proximity Read ↗

Optimal treatment duration for patients with HCV genotype 1 infection.Semantic proximity Read ↗

Prolonged PEG-IFN and RBV is effective in patients with HCV genotype 1 and high viral load who achieved virological response later than 24 weeks.Semantic proximity Read ↗

Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.Semantic proximity Read ↗

Expert opinion on the treatment of patients with chronic hepatitis C.Semantic proximity Read ↗

Impact of shorter duration of treatment on virological response rate in genotype 2 or 3 chronic hepatitis C virus infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.